This is an open-label, non-randomized study to determine the excretion kinetics and mass balance of GDC-0810, and to determine metabolites present in blood, feces, and urine in healthy participants following a single 300-milligram (mg) oral dose of GDC-0810 containing approximately 100 microcuries of [14C] labeled GDC-0810 using conventional absorption, metabolism, and excretion (AME) methodology. The entire duration of the study is up to approximately 8 weeks.

Inclusion Criteria:

• Healthy participants with non-child bearing potential, non-pregnant, non-lactating and either post-menopausal or surgically sterile.
• Negative pregnancy test result at Screening and at Day -1.
• Body mass index of 18.5 to 29.9 kilogram per square meter.
• Healthy condition documented with no clinically significant findings from laboratory evaluations, medical history, 12-lead electrocardiograms, and vital signs.

Exclusion Criteria:

• Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastric, neurological, or psychiatric disorder.
• History of significant hypersensitivity or allergy to any drug.
• Uncontrolled hypothyroidism.
• History or presence of clinically significant abnormal electrocardiogram.
• History of venous thrombosis, endometrial disorders, thrombophilic condition, inflammatory bowel disease, chronic diarrhoea, active or latent tuberculosis, and Gilbert's syndrome.
• Major surgical procedure or significant traumatic injury within 3 months prior to study participation.
• Participation in more than one other radiolabeled investigational drug study within 12 months prior to Check-in (Day -1).
• Exposure to significant radiation occuring within 12 months prior to Check-in (Day -1).
• Any acute or chronic condition that would limit the participant's ability to participate in the clinical study.
• Failure to satisfy the Investigator of fitness to participate for any other reason.